Infection Control in Cancer Therapy Market size is estimated to be USD 2.5 Billion in 2024 and is expected to reach USD 4.8 Billion by 2033 at a CAGR of 7.5% from 2026 to 2033.
In the realm of cancer therapy, infection control stands as a pivotal concern, especially within Europe's healthcare landscape. Patients undergoing treatments such as chemotherapy and radiation often experience compromised immune systems, rendering them more susceptible to infections. This heightened vulnerability necessitates stringent infection control measures to ensure patient safety and optimal therapeutic outcomes.
Within the European infection control market, a significant emphasis is placed on consumables, including sterilization supplies, disinfectants, and protective apparel. These items are indispensable in maintaining aseptic environments across various healthcare settings. Notably, the market witnessed a revenue of approximately $15.2 billion in 2023, with projections indicating a growth to nearly $23 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.1% during the forecast period. This upward trajectory underscores the escalating demand for infection control solutions in the region.
Healthcare facilities are increasingly adopting advanced technologies to bolster infection prevention. For instance, the integration of automated ultraviolet (UV) light germicidal devices has gained traction. These devices have demonstrated efficacy in reducing total aerobic colony counts by 90%, surpassing the 76% reduction achieved through manual cleaning methods. Such innovations play a crucial role in mitigating the risk of healthcare-associated infections, thereby enhancing patient safety.
Moreover, environmental cleaning protocols have evolved to address the resilience of pathogens on surfaces. Research indicates that certain organisms can survive on surfaces for extended periods—over 12 days for some viruses, up to 2 months for methicillin-resistant Staphylococcus aureus (MRSA), and as long as 36 months for vancomycin-resistant enterococci (VRE). This persistence underscores the necessity for rigorous and effective cleaning strategies within healthcare environments.
Infection control programs also encompass measures to prevent device-related infections, particularly those associated with central venous catheters. These catheters, commonly used in oncology patients, are linked to an increased risk of bloodstream infections. Implementing aseptic techniques during catheter insertion and adhering to post-insertion care bundles have been shown to decrease infection rates, especially for short-term catheters.
Addressing the challenges posed by multidrug-resistant organisms (MDROs) remains a critical aspect of infection control. Patients with hematologic malignancies and hematopoietic cell transplants are at heightened risk, with associated mortality rates reaching up to 80%. Comprehensive strategies, including active screening, contact precautions, and antimicrobial stewardship, are essential to curb the transmission of MDROs within healthcare settings.
In the context of cancer therapy, maintaining a protective environment is paramount. This includes controlling air quality and water sources to minimize exposure to potential pathogens. Facilities treating hematopoietic cell transplant recipients often employ high-efficiency particulate air (HEPA) filters and laminar airflow units to reduce the risk of aspergillosis, a serious fungal infection. Such environmental controls are integral components of comprehensive infection control programs.
In conclusion, the landscape of infection control in cancer therapy within Europe is characterized by a dynamic interplay of advanced technologies, stringent protocols, and continuous vigilance. The projected growth of the infection control market reflects the ongoing commitment to enhancing patient safety and improving therapeutic outcomes. As healthcare facilities continue to adopt innovative solutions and refine existing practices, the overarching goal remains steadfast: to protect vulnerable patients and ensure the highest standards of care in oncology settings.
Get an In-Depth Research Analysis of the Europe Infection Control in Cancer Therapy Market Size And Forecast [2025-2032]
Kimberly Clark Corporation
3M Healthcare Company
Honeywell International
Getinge Group AB
Sterigenics International
Sakura Global Holding Company
Arizant Healthcare Inc.
Nordion
Cisa S.P.A.
Steris Corporation
Nordion
Ahlstrom Filtration LLC
Membrana GmbH
Synergy Health
Plc
Advanced Sterilization Products Services
Inc
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Europe region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Infection Control in Cancer Therapy Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Infection Control in Cancer Therapy Market
Disinfectants
Antiseptics
Personal Protective Equipment (PPE)
Infection Control Consumables
Other Infection Control Products
Bacterial Infections
Viral Infections
Fungal Infections
Parasitic Infections
Hospitals
Oncology Clinics
Home Healthcare Providers
Long-term Care Facilities
Research Institutes
Topical Applications
Internal Administration
Preventive Protocols
Environmental Controls
Online Sales
Retail Pharmacies
Hospital Pharmacies
Direct Sales
Distribution Partners
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
For More Information or Query, Visit @ Infection Control in Cancer Therapy Market Research Analysis
1. Introduction of the Europe Infection Control in Cancer Therapy Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Market Size And Trends
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Infection Control in Cancer Therapy Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Infection Control in Cancer Therapy Market, By Type
6. Europe Infection Control in Cancer Therapy Market, By Application
7. Europe Infection Control in Cancer Therapy Market, By Geography
Europe
8. Europe Infection Control in Cancer Therapy Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Market Size And Trends
Market Size And Trends is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.marketsizeandtrends.com/